cbdMD Therapeutics Announces Launch Of Animal Health Study In Collaboration With Colorado State University’s Veterinary Pro...
June 03 2021 - 10:00AM
Business Wire
Study To Explore Effects of cbdMD’s
Proprietary Cannabinoid Blend On Pets Who Suffer From
Osteoarthritis
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the “Company”), one
of the leading, and most highly trusted and recognized cannabidiol
(CBD) company, announced today that its recently formed subsidiary,
cbdMD Therapeutics, has begun a collaboration with researchers at
the Colorado State University (CSU) veterinary program, to explore
the effects of the Company’s patent pending, proprietary cbdMD
branded cannabinoid blend on dogs that suffer from osteoarthritis.
The results from this study will provide validating data on the
efficacy of the Company's products in reducing pain and improving
joint mobility in dogs. The Company expects the full study to be
complete by the Spring 2022. cbdMD’s Paw CBD brand is one of the
leading CBD animal health brands in the U.S.
“It has been estimated that one in five dogs are diagnosed with
osteoarthritis in their lifetime. With almost 1 billion dogs
globally and over 75 million in the US, osteoarthritis effects
millions of our loved ones. Paw CBD is committed to providing
products that can improve our pet’s quality of life and provide
relief for joint discomfort for the millions of pets who suffer
from this disease. Our partnership with CSU will serve as the
foundation for future work where we will explore the clinical
impact of our proprietary broad spectrum cannabinoid blend on pain
and mobility in our pets,” said Martin Sumichrast, Chairman and
Co-CEO of cbdMD, Inc.
About cbdMD, Inc.
cbdMD, Inc. is one of the leading and most highly trusted and
most recognized cannabidiol (CBD) brands with a comprehensive line
of U.S. produced, THC-free1 CBD products. Our cbdMD brand currently
includes over 130 SKUs of high-grade, premium CBD products
including CBD tinctures, CBD gummies, CBD topicals, CBD capsules,
CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes.
Our Paw CBD brand of pet products includes over 45 SKUs of
veterinarian-formulated products including tinctures, chews,
topicals products in varying strengths, and our CBD Botanicals
brand of beauty and skincare products features 15 SKUs, including
facial oil and serum, toners, moisturizers, clear skin, facial
masks, exfoliants and body care. To learn more about cbdMD and
their comprehensive line of U.S. grown, THC-free1 CBD oil products,
please visit www.cbdmd.com, follow cbdMD on Instagram and Facebook,
or visit one of the 6,000 retail outlets that carry cbdMD
products.
1 THC-free is defined as below the level of detection using
validated scientific analytical methods.
Forward-Looking Statements
This press release contains certain forward-looking statements
that are based upon current expectations and involve certain risks
and uncertainties within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements can
be identified by the use of words such as ''should,'' ''may,''
''intends,'' ''anticipates,'' ''believes,'' ''estimates,''
''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and
''proposes.'' These forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties, and
other factors, some of which are beyond our control and difficult
to predict and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements
including our ability to meet our net sales guidance for the first
quarter of fiscal 2022. You are urged to carefully review and
consider any cautionary statements and other disclosures, including
the statements made under the heading "Risk Factors" in cbdMD,
Inc.'s Annual Report on Form 10-K for the fiscal year ended
September 30, 2020 as filed with the Securities and Exchange
Commission (the "SEC") on December 22, 2020, Item 1A. Risk Factors,
contained in our Quarterly Report on Form 10-Q for the period ended
March 31, 2021 as filed with the SEC on May 12, 2021 and our other
filings with the SEC. All forward-looking statements involve
significant risks and uncertainties that could cause actual results
to differ materially from those in the forward-looking statements,
many of which are generally outside the control of cbdMD, Inc. and
are difficult to predict. cbdMD, Inc. does not undertake any duty
to update any forward-looking statements except as may be required
by law. The information which appears on our websites and our
social media platforms, including, but not limited to, Instagram
and Facebook, is not part of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603005549/en/
PR: 5W Public Relations cbdMD@5wpr.com (212) 999-5585 Investors:
cbdMD, Inc. John Weston Director of Investor Relations
John.Weston@cbdMD.com (704) 249-9515
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Apr 2023 to Apr 2024